Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Vaccine for Killer Disease One Step Closer

Published: Monday, November 19, 2012
Last Updated: Sunday, November 18, 2012
Bookmark and Share
New 4CMenB vaccine designed to cover most strains of the disease in Europe.

Leading meningitis charity Meningitis Research Foundation (MRF) has welcomed the news that a potentially lifesaving vaccine to prevent MenB is one step closer with positive opinion by the European Medicines Agency (EMA).

The vaccine, 4CMenB produced by Novartis Vaccines and Diagnostics Limited is the first ever vaccine against meningococcal B meningitis and septicaemia (MenB) designed to cover most strains of the disease in Europe.

MenB is responsible for an average of 1870 cases across the UK each year, mostly in young children.

Around 1 in 10 people affected will die, and a further 1 in 10 survivors will be left with serious after-effects, such as limb amputations, deafness, blindness, and brain damage.

The new vaccine will require a license from the European Commission before European governments can consider it for implementation.

The UK Government takes vaccination advice from the Joint Committee on Vaccination and Immunization.

If they recommend the new MenB vaccine, the earliest it could be implemented in the UK would be the end of 2013.

Chris Head, Chief Executive of Meningitis Research Foundation said: “We have a vision of a world free from meningitis and septicaemia so this news is a huge boost for our members and their families, and for doctors and scientists who have all worked tirelessly against this devastating disease. Since the first meningitis vaccine was introduced in 1992, many strains of meningitis including Hib, MenC and pneumococcal have been dramatically reduced. Once the MenB vaccine is licensed, it is essential that Government give it full consideration as soon as possible, especially given the shocking lifetime costs to people who survive MenB and are left with serious, life-long disabilities. We must not allow children to die from this disease if it can be prevented.”

MRF Trustee Professor George Griffin, professor of Infectious Diseases and Medicine at St George’s University of London said: “This vaccine is a real step forward and will have a major impact on MenB cases. However, meningitis will remain a major clinical problem and research into microbial causes continues to be a priority alongside raising public awareness of the symptoms.”

Paralympics reporter and keen equestrian Diana Man (30) from Tunbridge Wells is building a new life after contracting MenB in November 2007 which left her without her lower legs, her fingers and with epilepsy.

She said: “My life has changed a great deal since getting MenB, but I have learned to adjust and manage just like anyone else. If a vaccine has been produced to prevent this disease it should be made available as soon as possible to prevent anyone else having to face the difficulties myself and others face in the future both physically, emotionally and financially.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos